ArticleThe American journal of pathology2001
Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.
Article in The American journal of pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE).Nature biotechnology · 2008Guideline
- Bridging Cancer and COVID-19: The Complex Interplay of ACE2 and TMPRSS2.Cancer medicine · 2025Review
- A heterogeneous information network learning model with neighborhood-level structural representation for predicting lncRNA-miRNA interactions.Computational and structural biotechnology journal · 2024Article
- Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation.Oncogene · 2021Article
- The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment.Journal of xenobiotics · 2021Review
- Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82.BMC cancer · 2020Article
- Article
- Dual Laplacian regularized matrix completion for microRNA-disease associations prediction.RNA biology · 2019Article
- Integrating random walk and binary regression to identify novel miRNA-disease association.BMC bioinformatics · 2019Article
- A Novel Method for Predicting Disease-Associated LncRNA-MiRNA Pairs Based on the Higher-Order Orthogonal Iteration.Computational and mathematical methods in medicine · 2019Article
- A Novel Model for Predicting Associations between Diseases and LncRNA-miRNA Pairs Based on a Newly Constructed Bipartite Network.Computational and mathematical methods in medicine · 2018Article
- TLHNMDA: Triple Layer Heterogeneous Network Based Inference for MiRNA-Disease Association Prediction.Frontiers in genetics · 2018Article
- Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.Oncogene · 2017Article
- MCMDA: Matrix completion for MiRNA-disease association prediction.Oncotarget · 2017Article
- Receptor tyrosine kinase Met promotes cell survival via kinase-independent maintenance of integrin α3β1.Molecular biology of the cell · 2016Article
- Transient receptor potential melastatin 4 channel contributes to migration of androgen-insensitive prostate cancer cells.Oncotarget · 2015Article
- Differential Redox Regulation of Ca²⁺ Signaling and Viability in Normal and Malignant Prostate Cells.Biophysical journal · 2015Article
- DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.Oncotarget · 2015Article
- Knockdown of WAVE3 impairs HGF induced migration and invasion of prostate cancer cells.Cancer cell international · 2015Article
- The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.Cancer discovery · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocyte growth factor/scatter factor (HGF/SF) promotes the proliferation, differentiation, motility, and invasion of epithelial cells by binding to its cell surface receptor, the Met tyrosine kinase. In the prostate, Met is expressed predominantly by prostate epithelial cells (PrEC), whereas HGF/SF is synthesized by prostate stromal cells (PrSC). Met is also expressed in localized and metastatic prostate cancers. Our results show that PrECs in in vitro culture maintain expression of Met at a level comparable to DU145 cancer cell expression. HGF/SF secreted by PrSC stimulates tyrosine phosphorylation of the Met receptor. In normal PrEC, HGF/SF causes growth inhibition, sustained phosphorylation of mitogen-activated protein kinase, and increased CK18 expression consistent with cell differentiation. In contrast, HGF/SF significantly stimulates the proliferation of DU145 prostate cancer cells. HGF/SF in the conditioned medium of PrSC specifically induces migration of both normal and malignant prostate epithelial cells through MatriGel-coated Transwell filters. HGF/SF depletion reduces cell migration by approximately 50%. The response of PrEC is specific for HGF/SF since the other growth factors tested do not significantly affect growth or migration of PrECs. These results support the in vivo importance of the prostate stroma and specifically of HGF/SF as a unique stromal derived factor in the development and progression of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.